Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | FPR1 | P21462 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14353917 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3BACE1KCNH2 | |
| SCHEMBL1818053 | 0.86 | KCNH2 (0.47) | BACE1KCNH2KDM1AMAOAMAOB | |
| SCHEMBL1818050 | 0.86 | KCNH2 (0.47) | BACE1KCNH2KDM1AMAOAMAOB | |
| SCHEMBL1818047 | 0.86 | KCNH2 (0.47) | BACE1KCNH2KDM1AMAOAMAOB | |
| SCHEMBL23941884 | 0.85 | KCNH2 (0.47) | KCNH2KDM1AMAOAMAOBCHRNB2 | |
| SCHEMBL16033453 | 0.85 | SLC6A3 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL16070070 | 0.85 | SLC6A3 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2306589 | 0.85 | SLC6A4 (0.50) | SLC6A4SLC6A3 | |
| SCHEMBL16033454 | 0.85 | SLC6A3 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL27405566 | 0.85 | SLC6A4 (0.50) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| EP-3150578-B1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-14 | — | — | EP | disclosed |
| EP-3150578-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | SLC6A2 1851/4885SLC6A4 3504/4885SLC6A3 2396/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | SLC6A2 1851/4885SLC6A4 3504/4885SLC6A3 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.